5 Biotechnology Stocks to Buy Now

ARIA, NBIX, ARRY, CLDX, INSM improve in weekly rankings

   
5 Biotechnology Stocks to Buy Now

Five biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

This week, ARIAD Pharmaceuticals, Inc. (ARIA) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The stock price has risen 29.6% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

Neurocrine Biosciences, Inc. (NBIX) earns a B this week, jumping up from last week’s grade of C. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

Array BioPharma (ARRY) boosts its rating from a C to a B this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.

Celldex Therapeutics, Inc. (CLDX) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.

This week, Insmed Incorporated’s (INSM) ratings are up from a C last week to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/11/5-biotechnology-stocks-to-buy-now-aria-nbix-arry-21/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.